All studies
Oncology · Registry · Sweden

Al-kassab-Cordova 2025

Postmenopausal breast cancer

Effect of dispensationSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Five-year all-cause mortality
vs BIG 1-98·HR·Efficacy
0.910.75–1.11
1.090.89–1.34
overlapPartial alignment1.25 SE apart

Design and methods

Estimand
Effect of dispensation
Design hypothesis
Superiority
Matching / weighting
Inverse-probability weighting
Analysis method
Weighted Cox proportional hazards model
Missing data
Complete case
DAG
No
QBA
No

Data and sample

Data type
Registry
Data sources
Multiple linked national registers
Geography
Sweden
Eligible sample
12536
Treated
8030
Control
4506
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
Funding
Declared: Public
Funders
Swedish public research funders reported in the manuscript

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2025_AlkassabCordova_BreastCancer
DOI
10.1093/aje/kwaf183
Affiliations
Swedish academic and national registry institutions
Sector
Academia
Target trials (study level)
BIG 1-98
Registration
NCT00004205